

Tillotts Pharma Transfers of Value in 2016 to Russian Healthcare Professionals and Healthcare Organisations

Date of publication: June 2017

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)										
					N/A	N/A					
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons										
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A				
	Number of Recipients in aggregate disclosure					N/A	N/A				
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A				
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)										
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons										
	Aggregate amount attributable to transfers of value to such Recipients										
	Number of Recipients in aggregate disclosure										
R & D	AGGREGATE DISCLOSURE										
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										EUR 146'497

Methodological Notes

Disclosure by Tillotts Pharma of payments to Russian healthcare professionals and healthcare organisations in 2016

Section VII of the Association of International Pharmaceutical Manufacturers Code of Practice (the AIPM Code) mandates the public disclosure in 2017 of certain transfers of value made by pharmaceutical companies during 2016 to Russian healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, www.tillotts.com.

The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding.

VAT

VAT is excluded from all disclosures of transfer of value.

Currency

All disclosures are made in Euros (€). Where the original payment was made in another currency, the sum was converted to Euros at the average annual exchange rate.

Consolidated Disclosures of the Corporate Group and Cross-border Payments

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. The disclosures for 2016 represent payments by Tillotts Pharma AG.

Multi-year contracts

Where multi-year contracts are included in the disclosure data, the disclosures related to such multi-year contracts represent the services rendered and paid for in calendar year 2016 under such contracts.

Data included

The data disclosed by Tillotts Pharma is consistent with the requirements of the AIPM Code. The data can be categorised as follows:

Research & Development

Research & Development transfers of value are disclosed in the aggregate and encompass transfers of value to Russian healthcare professionals and healthcare organisations related to the planning and/or conduct of a clinical trial, as well as costs that are subsidiary to these activities.